HSV-2: in Pursuit of a Vaccine

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2011 Dec 3

PMID 22133885

Citations 60

Authors

Christine Johnston

David M Koelle

Anna Wald

Affiliations

Soon will be listed here.

Abstract

Herpes simplex virus type 2 (HSV-2) is one of the most prevalent sexually transmitted infections worldwide. In addition to recurrent genital ulcers, HSV-2 causes neonatal herpes, and it is associated with a 3-fold increased risk for HIV acquisition. Although many HSV-2 vaccines have been studied in animal models, few have reached clinical trials, and those that have been tested in humans were not consistently effective. Here, we review HSV-2 pathogenesis, with a focus on novel understanding of mucosal immunobiology of HSV-2, and vaccine efforts to date, in an attempt to stimulate thinking about future directions for development of effective prophylactic and therapeutic HSV-2 vaccines.

Citing Articles

Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy.

Atanasiu D, Saw W, Friedman H, Cohen G Viruses. 2025; 17(2).

PMID: 40007004 PMC: 11860751. DOI: 10.3390/v17020249.

Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4 and CD8 T cells and protects against recurrent....

Quadiri A, Prakash S, Dhanushkodi N, Singer M, Zayou L, Shaik A J Virol. 2024; 98(5):e0159623.

PMID: 38587378 PMC: 11092353. DOI: 10.1128/jvi.01596-23.

Immunogenicity and Therapeutic Efficacy of a Sendai-Virus-Vectored HSV-2 Vaccine in Mouse and Guinea Pig Models.

Ren X, Su W, Li S, Zhao T, Huang Q, Wang Y Vaccines (Basel). 2023; 11(12).

PMID: 38140157 PMC: 10747028. DOI: 10.3390/vaccines11121752.

CCL28 Enhances HSV-2 gB-Specific Th1-Polarized Immune Responses against Lethal Vaginal Challenge in Mice.

Yan Y, Hu K, Fu M, Deng X, Guan X, Luo S Vaccines (Basel). 2022; 10(8).

PMID: 36016177 PMC: 9415327. DOI: 10.3390/vaccines10081291.

Is the ZIKV Congenital Syndrome and Microcephaly Due to Syndemism with Latent Virus Coinfection?.

Grayo S Viruses. 2021; 13(4).

PMID: 33924398 PMC: 8069280. DOI: 10.3390/v13040669.

References

Spector F, Kern E, Palmer J, Kaiwar R, Cha T, Brown P . Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis. 1998; 177(5):1143-54. DOI: 10.1086/515278. View

Casrouge A, Zhang S, Eidenschenk C, Jouanguy E, Puel A, Yang K . Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006; 314(5797):308-12. DOI: 10.1126/science.1128346. View

Alsallaq R, Schiffer J, Longini Jr I, Wald A, Corey L, Abu-Raddad L . Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis. 2010; 37(5):290-7. PMC: 2860045. DOI: 10.1097/OLQ.0b013e3181d3d023. View

Koelle D, Corey L . Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003; 16(1):96-113. PMC: 145296. DOI: 10.1128/CMR.16.1.96-113.2003. View

Hoshino Y, Pesnicak L, Dowdell K, Burbelo P, Knipe D, Straus S . Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis. 2009; 200(7):1088-95. PMC: 3826825. DOI: 10.1086/605645. View

Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S . Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371(9630):2109-19. PMC: 2650104. DOI: 10.1016/S0140-6736(08)60920-4. View

Mertz G, Ashley R, Burke R, Benedetti J, Critchlow C, Jones C . Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990; 161(4):653-60. DOI: 10.1093/infdis/161.4.653. View

Schmidt O, Fife K, Corey L . Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis. 1984; 149(4):645-6. DOI: 10.1093/infdis/149.4.645. View

Looker K, Garnett G, Schmid G . An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008; 86(10):805-12, A. PMC: 2649511. DOI: 10.2471/blt.07.046128. View

10.

Schiffer J, Abu-Raddad L, Mark K, Zhu J, Selke S, Magaret A . Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2010; 1(7):7ra16. PMC: 2818652. DOI: 10.1126/scitranslmed.3000193. View

11.

Verjans G, Hintzen R, van Dun J, Poot A, Milikan J, Laman J . Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A. 2007; 104(9):3496-501. PMC: 1805572. DOI: 10.1073/pnas.0610847104. View

12.

Khanna K, Bonneau R, Kinchington P, Hendricks R . Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003; 18(5):593-603. PMC: 2871305. DOI: 10.1016/s1074-7613(03)00112-2. View

13.

Gebhardt T, Wakim L, Eidsmo L, Reading P, Heath W, Carbone F . Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009; 10(5):524-30. DOI: 10.1038/ni.1718. View

14.

Schwartz E, Blower S . Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis. 2005; 191(10):1734-46. DOI: 10.1086/429299. View

15.

Cotter C, Nguyen M, Yount J, Lopez C, Blaho J, Moran T . The virion host shut-off (vhs) protein blocks a TLR-independent pathway of herpes simplex virus type 1 recognition in human and mouse dendritic cells. PLoS One. 2010; 5(2):e8684. PMC: 2823768. DOI: 10.1371/journal.pone.0008684. View

16.

Straus S, Corey L, Burke R, Savarese B, Barnum G, Krause P . Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994; 343(8911):1460-3. DOI: 10.1016/s0140-6736(94)92581-x. View

17.

Yim K, Carroll C, Tuyama A, Cheshenko N, Carlucci M, Porter D . The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol. 2005; 79(23):14632-9. PMC: 1287570. DOI: 10.1128/JVI.79.23.14632-14639.2005. View

18.

Freeman E, White R, Bakker R, Orroth K, Weiss H, Buve A . Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine. 2008; 27(6):940-6. PMC: 2686080. DOI: 10.1016/j.vaccine.2008.11.074. View

19.

de Bruyn G, Vargas-Cortez M, Warren T, Tyring S, Fife K, Lalezari J . A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2005; 24(7):914-20. DOI: 10.1016/j.vaccine.2005.08.088. View

20.

Langenberg A, Burke R, Adair S, Sekulovich R, Tigges M, Dekker C . A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med. 1995; 122(12):889-98. DOI: 10.7326/0003-4819-122-12-199506150-00001. View